{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:52:44Z","timestamp":1792623164493,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Macrophage activation syndrome (MAS) developed under tocilizumab treatment poses a diagnostic challenge. This study aims to demonstrate the frequency and the clinical features of MAS developed in patients with adult-onset Still\u2019s disease (AOSD) receiving tocilizumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The consecutive AOSD patients treated with tocilizumab in our institution from April 2008 to March 2020 were studied. The frequency of clinically diagnosed MAS during tocilizumab treatment, their conformity to the several criteria relevant for MAS, and laboratory characteristics compared to AOSD flare were investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 20 AOSD patients treated with tocilizumab, six developed clinically diagnosed MAS, four immediately after starting tocilizumab and two after long-term treatment. Some of them had already met the MAS criteria before starting tocilizumab. At MAS diagnosis, although some did not meet the MAS criteria due to lack of fever and\/or the lower ferritin levels, all consistently showed sharp increases in ferritin along with marked abnormal changes in two or more different markers of organ damage, unlike the AOSD flares.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>MAS is not a rare complication in AOSD patients receiving tocilizumab. The clinical similarities between systemic AOSD and MAS, and substantial alterations in MAS features by inhibition of interleukin-6 signaling may limit the utility of the existing diagnostic\/classification criteria in diagnosing MAS under tocilizumab treatment. The emergence of abnormalities in MAS-related organ damage markers with a rapid elevation of ferritin should be considered as MAS development in AOSD patients receiving tocilizumab even if the patients are afebrile or have relatively low ferritin levels.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1080\/14397595.2021.1899565","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T11:12:14Z","timestamp":1615374734000},"page":"169-176","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Macrophage activation syndrome in patients with adult-onset Still\u2019s disease under tocilizumab treatment: A single-center observational study"],"prefix":"10.1093","volume":"32","author":[{"given":"Toru","family":"Yamabe","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Nagoya City University Hospital, Nagoya, Japan"},{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Ohmura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Uehara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Nagoya City University Hospital, Nagoya, Japan"},{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-2611","authenticated-orcid":false,"given":"Taio","family":"Naniwa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Nagoya City University Hospital, Nagoya, Japan"},{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"issue":"10","key":"2022010903465754700_R1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"2022010903465754700_R2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000312628","article-title":"Macrophage activation syndrome in autoimmune disease","volume":"153","author":"Deane","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"issue":"7","key":"2022010903465754700_R3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset Still\u2019s disease","volume":"13","author":"Gerfaud-Valentin","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"3","key":"2022010903465754700_R4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/14397595.2014.974881","article-title":"Nationwide epidemiological survey of 169 patients with adult Still\u2019s disease in Japan","volume":"25","author":"Asanuma","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"1","key":"2022010903465754700_R5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12916-016-0738-8","article-title":"Adult-onset Still\u2019s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers","volume":"14","author":"Ruscitti","year":"2016","journal-title":"BMC Med"},{"issue":"10","key":"2022010903465754700_R6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00296-016-3546-8","article-title":"Epidemiological study of adult-onset Still\u2019s disease using a Japanese administrative database","volume":"36","author":"Sakata","year":"2016","journal-title":"Rheumatol Int"},{"issue":"7","key":"2022010903465754700_R7","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/rheumatology\/kez622","article-title":"Clinical characteristics and comorbidities in adult-onset Still\u2019s disease using a large US administrative claims database","volume":"59","author":"Lenert","year":"2020","journal-title":"Rheumatology"},{"issue":"25","key":"2022010903465754700_R8","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2022010903465754700_R9","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still\u2019s disease: multicenter retrospective open-label study of thirty-four patients","volume":"66","author":"Ortiz-Sanju\u00e1n","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"2022010903465754700_R10","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2022010903465754700_R11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/s10165-010-0348-9","article-title":"Benefit and a possible risk of tocilizumab therapy for adult-onset Still\u2019s disease accompanied by macrophage-activation syndrome","volume":"21","author":"Kobayashi","year":"2011","journal-title":"Mod Rheumatol"},{"key":"2022010903465754700_R12","first-page":"923497","article-title":"Successful use of higher-dose etanercept for multirefractory systemic flare of adult-onset Still\u2019s disease with liver failure with no response to tocilizumab therapy","volume":"2013","author":"Naniwa","year":"2013","journal-title":"Case Rep Rheumatol"},{"key":"2022010903465754700_R13","first-page":"1","article-title":"Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset Still\u2019s disease with a previous successful tocilizumab treatment","author":"Naniwa","year":"2020","journal-title":"Mod Rheumatol Case Rep"},{"issue":"2","key":"2022010903465754700_R14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3899\/jrheum.130881","article-title":"Tocilizumab in adult-onset Still\u2019s disease: the Israeli experience","volume":"41","author":"Elkayam","year":"2014","journal-title":"J Rheumatol"},{"issue":"2","key":"2022010903465754700_R15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/14397595.2014.899178","article-title":"Successful tocilizumab therapy in seven patients with refractory adult-onset Still\u2019s disease","volume":"26","author":"Bannai","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"3","key":"2022010903465754700_R16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1080\/14397595.2016.1221875","article-title":"Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still\u2019s disease","volume":"27","author":"Tsuchida","year":"2017","journal-title":"Mod Rheumatol"},{"issue":"1","key":"2022010903465754700_R17","doi-asserted-by":"crossref","first-page":"13477","DOI":"10.1038\/s41598-017-13639-y","article-title":"A pilot study on tocilizumab for treating refractory adult-onset Still\u2019s","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"2022010903465754700_R18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/acr.23277","article-title":"Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","volume":"70","author":"Schulert","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2022010903465754700_R19","first-page":"424","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"issue":"2","key":"2022010903465754700_R20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult Still\u2019s disease: manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2022010903465754700_R21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2022010903465754700_R22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/art.39332","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2022010903465754700_R23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00296-018-4114-1","article-title":"Are the 2016 EULAR\/ACR\/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still\u2019s disease?","volume":"39","author":"Tada","year":"2019","journal-title":"Rheumatol Int"},{"issue":"9","key":"2022010903465754700_R24","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"2022010903465754700_R25","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2019-215211","article-title":"Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"78","author":"Minoia","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022010903465754700_R26","article-title":"Application of MS score in macrophage activation syndrome patients associated with adult onset Still\u2019s disease","author":"Wang","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2022010903465754700_R27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/24725625.2020.1741073","article-title":"Successful use of short-term add-on tocilizumab for refractory adult-onset still\u2019s disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide","volume":"4","author":"Ohmura","year":"2020","journal-title":"Mod Rheumatol Case Rep"},{"issue":"1","key":"2022010903465754700_R28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ard.2008.088179","article-title":"Tocilizumab for multirefractory adult-onset Still\u2019s disease","volume":"68","author":"De Bandt","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2022010903465754700_R29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/03009742.2017.1314003","article-title":"Spontaneous resolution of Epstein-Barr virus-induced haemophagocytic lymphohistiocytosis in Still\u2019s disease treated by tocilizumab: a case report","volume":"47","author":"Ebstein","year":"2018","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"2022010903465754700_R30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.semarthrit.2015.11.002","article-title":"Macrophage activation syndrome complicating adult onset Still\u2019s disease: a single center case series and comparison with literature","volume":"45","author":"Lenert","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"2022010903465754700_R31","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1097\/MD.0000000000000451","article-title":"Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients","volume":"94","author":"Bae","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2022010903465754700_R32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset Still\u2019s disease: comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"Inoue","year":"2016","journal-title":"Clin Immunol"},{"issue":"12","key":"2022010903465754700_R33","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s10067-017-3830-3","article-title":"Macrophage activation syndrome in Still\u2019s disease: analysis of clinical characteristics and survival in paediatric and adult patients","volume":"36","author":"Ruscitti","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"6","key":"2022010903465754700_R34","first-page":"996","article-title":"Clinical characteristics and treatment outcomes of macrophage activation syndrome in adults: a case series of 67 patients","volume":"51","author":"Yao","year":"2019","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"issue":"4","key":"2022010903465754700_R35","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3899\/jrheum.140288","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab","volume":"42","author":"Yokota","year":"2015","journal-title":"J Rheumatol"},{"issue":"5","key":"2022010903465754700_R36","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3899\/jrheum.090662","article-title":"Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases","volume":"37","author":"Maruyama","year":"2010","journal-title":"J Rheumatol"},{"issue":"13","key":"2022010903465754700_R37","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2022010903465754700_R38","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2022010903465754700_R39","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2022010903465754700_R40","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2022010903465754700_R41","doi-asserted-by":"crossref","first-page":"e000161","DOI":"10.1136\/rmdopen-2015-000161","article-title":"Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"2","author":"Ravelli","year":"2016","journal-title":"RMD Open"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1080\/14397595.2021.1899565\/41818646\/1899565.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/1\/169\/42083426\/1899565.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/1\/169\/42083426\/1899565.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:56:07Z","timestamp":1642560967000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/1\/169-176\/6469735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,4,6]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1080\/14397595.2021.1899565","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,4,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}